Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%

Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr

Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Fortis Healthcare Q2 FY25 PAT up 5% at Rs. 193 Cr

Hospital business revenues increase 13.9% to Rs. 1,655 crore

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore

GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr

The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market

Mankind Pharma completes acquisition of BSV

Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.

Sumitomo Corporation entered into contract with Revorf

Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies

Gland Pharma appoints Shyamakant Giri as CEO

Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals